Market Overview

Benzinga's Top Downgrades

Share:
Benzinga's Top Downgrades
Related TEVA
Report Sees 'Cognitive Dissonance' In Mylan's Internal Price Target
Analyst: Mylan Shareholders Might Get Convinced By Vigodman Letter
Mylan Q1 Mixed; Abiomed, Mallinckrodt, Zoetis Beat (Investor's Business Daily)
Related QEP
Markets Inch Higher Following Encouraging Beige Book Commentary
Worst Performing Industries For November 28, 2014

Analysts at JP Morgan downgraded Teva Pharmaceutical Industries (NYSE: TEVA) from “overweight” to “neutral.” The target price for Teva has been lowered from $45 to $43. Teva's shares closed at $38.88 yesterday.

Deutsche Bank downgraded QEP Resources (NYSE: QEP) from “buy” to “hold.” The target price for QEP Resources has been lowered from $37 to $34. QEP Resources' shares closed at $28.78 yesterday.

Baird downgraded Brady (NYSE: BRC) from “outperform” to “neutral.” The target price for Brady has been lowered from $41 to $33. Brady's shares closed at $30.52 yesterday.

Analysts at DA Davidson downgraded Under Armour (NYSE: UA) from “buy” to “neutral.” Under Armour's shares closed at $80.59 yesterday.

Latest Ratings for TEVA

DateFirmActionFromTo
Apr 2015Standpoint ResearchUpgradesHoldBuy
Apr 2015Argus ResearchMaintainsBuy
Apr 2015BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for TEVA
View the Latest Analyst Ratings

Posted-In: Top DowngradesDowngrades Analyst Ratings

 

Related Articles (BRC + QEP)

Around the Web, We're Loving...